HeXun Biosciences CoROCO:6986 23 EBITDA Margin % is 55.89% as of Dec. 2025, which is 17% above its 10-year median of 47.91. GuruFocus rates ROCO:6986 with a GF Score™ of 23/100. The stock has 1 warning sign investors should review. Among 939 Biotechnology companies, HeXun Biosciences Co ranks better than 94.14% on this metric.
HeXun Biosciences Co (ROCO:6986) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
HeXun Biosciences Co EBITDA Margin % Related Terms
HeXun Biosciences Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for HeXun Biosciences Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6986 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, HeXun Biosciences Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HeXun Biosciences Co EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HeXun Biosciences Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where HeXun Biosciences Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HeXun Biosciences Co (ROCO:6986) has a EBITDA Margin % of 55.89% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on HeXun Biosciences Co and its competitors. This is 17% above median its historical median of 47.91. Over the past decade, HeXun Biosciences Co's EBITDA Margin % has ranged from 22.58 to 65.41. According to the industry distribution chart, HeXun Biosciences Co ranks #55 out of 939 companies in the Biotechnology industry, placing it in the top 5.9%.
Is HeXun Biosciences Co's EBITDA Margin % too high?
HeXun Biosciences Co's current EBITDA Margin % of 55.89% is 17% above median its 10-year median of 47.91. Over the past 10 years, this metric has ranged from a low of 22.58 to a high of 65.41. Based on the distribution chart, HeXun Biosciences Co ranks #55 out of 939 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, HeXun Biosciences Co has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does HeXun Biosciences Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, HeXun Biosciences Co ranks #55 out of 939 companies for EBITDA Margin %. This places HeXun Biosciences Co in the top 6% of its industry — outperforming the majority of peers. Historically, HeXun Biosciences Co's own EBITDA Margin % has ranged from 22.58 to 65.41 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on HeXun Biosciences Co and its competitors. HeXun Biosciences Co's current EBITDA Margin % is 55.89%, which is 17% above median its own 10-year median of 47.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HeXun Biosciences Co stock overvalued right now?
HeXun Biosciences Co (ROCO:6986) has a current EBITDA Margin % of 55.89%. The current EBITDA Margin % is 55.89%, which is 17% above median its 10-year median of 47.91. HeXun Biosciences Co's overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For HeXun Biosciences Co (ROCO:6986), the current EBITDA Margin % is 55.89% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
HeXun Biosciences Co Ltd is engaged in the research and development of cell drugs and cell derivatives. It conducts research and development jointly with medical research institutions to use stem cells to treat cardiovascular, immune-inflammatory, and neurodegenerative diseases to develop innovative cell drugs and treatment methods. The company's main business items are new drug research and development, biotechnology services, and research and development services, such as: commissioned research and development and production services for cell medicine, agency testing and development services, and biomedical consulting services, etc.
23GF Score
Get the complete analysis for ROCO:6986
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6986 has been successfully added to your 
